You are here: Industry Insights > Elzonris

News List

CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) prnasia
November 18, 2020
The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the approval of ..
Menarini to buy Stemline for up to $677 million pharmatimes
May 05, 2020
Menarini is to purchase Stemline Therapeutics in a deal valued at up to $677 million, establishing its presence in the US biopharma market.
FDA Approves Elzonris for BPDCN americanpharmaceuticalreview
December 27, 2018
The U.S. Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.....
FDA Approves Drugs for Treatment of Two Rare Blood Diseases drugs
December 25, 2018
Two drugs have been approved by the U.S. Food and Drug Administration for the treatment of rare blood diseases, the agency announced Friday....
FDA Approves Elzonris (tagraxofusp-erzs), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy drugs
December 24, 2018
Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.....
FDA Approves First Treatment for Rare Blood Disease americanpharmaceuticalreview
December 24, 2018
The U.S. Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.....